|
Lurbinectedin Clinical Trials
12 actively recruiting trials across 9 locations
▼ -1 trial since May 2026
Also known as: JZP712, PM01183, Zepzelca
Pipeline
Phase 1: 2Phase 2: 5Phase 3: 2Phase 1/2: 3
Top Sponsors
- VA Office of Research and Development1
- UNC Lineberger Comprehensive Cancer Center1
- National Cancer Institute (NCI)1
- M.D. Anderson Cancer Center1
- Luye Pharma Group Ltd.1
Indications
- Cancer12
- Lung Cancer8
- Small Cell Lung Cancer4
- Desmoplastic Small Round Cell Tumor2
- Relapsed Small Cell Lung Cancer2
Other2 trials
Los Angeles, California2 trials
Lurbinectedin in FET-Fused Tumors
Cedars-Sinai Medical Center
Phase 1/2
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Children's Hospital of Los Angeles
Phase 1/2
Springdale, Arkansas1 trial
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Highlands Oncology Group
Phase 3
Palo Alto, California1 trial
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
VA Palo Alto Health Care System, Palo Alto, CA
Phase 1/2
New Haven, Connecticut1 trial
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Yale University School of Medicine /ID# 278181
Phase 2
Atlanta, Georgia1 trial
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Emory University Hospital Midtown
Phase 1
Bethesda, Maryland1 trial
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Institutes of Health Clinical Center
Phase 2
Lebanon, New Hampshire1 trial
Study of Trilaciclib and Lurbinectidin
Dartmouth Hitchcock Medical Center
Phase 2
Philadelphia, Pennsylvania1 trial
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2
Houston, Texas1 trial
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M D Anderson Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.